chrysin

Overview

Chrysin is a naturally occurring flavonoid compound found in a variety of plant-derived materials, including propolis and medicinal plants. Chemically, it belongs to the flavone subclass of flavonoids and has attracted biomedical interest because of its reported antioxidant, anti-inflammatory, and enzyme-modulating properties in preclinical research. In the recent literature provided here, chrysin appears primarily as a bioactive phytochemical and as a computationally prioritized small molecule for disease-related target engagement.

Biologically, chrysin has been investigated in contexts involving neuroinflammation, renal injury, bacterial biofilm formation, and cancer-related signaling. The studies summarized below suggest that it may interact with proteins such as p38α, p38γ, and ERα, and may influence pathways associated with oxidative stress, inflammatory mediators such as IL18, Interleukin 1 beta, C-C motif chemokine ligand 2, and broader protective signaling networks including SIRT6/NRF2/GPX4 signaling pathway and superoxide dismutase-related antioxidant responses. However, the evidence in the provided sources is largely preclinical and computational, with only limited experimental validation.

Focus of Latest Publications

Recent publications have continued to examine chrysin as a bioactive flavonoid with potential therapeutic and predictive relevance across several disease contexts. In an experimental diethylnitrosamine-induced hepatocellular carcinoma rat model, chrysin was administered orally at 50 mg/kg for 8 weeks after tumor induction, either alone or in combination with apigenin. The study reported that DEN-induced HCC was associated with activation of tumor-promoting signaling markers, including survivin, annexin-V, smoothened, sonic hedgehog, jagged1, and notch1, together with reduced caspase-3 expression. Chrysin treatment was associated with marked reductions in fibrosis and inflammation relative to DEN alone, although the combination and apigenin groups showed the most pronounced effects overall.

Chrysin has also been investigated in renal injury, where it was evaluated for protection against tramadol-induced nephrotoxicity. In that study, tramadol increased serum creatinine and BUN, elevated renal damage biomarkers such as KIM-1, NGAL, FABP, IL-18, MCP-1, and YKL-40, and disrupted RNA networks, ketogenesis-related metabolites, and antioxidant defenses. Chrysin partially or substantially improved these biochemical, molecular, and metabolic abnormalities, including markers linked to oxidative stress and inflammation, and principal component analysis suggested a shift of the biomarker profile toward normal physiological levels.

Several recent in silico and computational studies have also highlighted chrysin as a candidate ligand or predicted bioactive compound. In a multimodal machine learning framework for molecular inhibitory activity and disease association prediction, chrysin was identified as a stable natural product inhibitor predicted against HLA-DRA in calcific aortic valve disease. In a CANDO-based multiscale drug discovery analysis for glioma, chrysin was among the investigational compounds predicted as a potential glioma treatment. In another in silico breast cancer study focused on p38α, p38γ, and ERα, the p38α-chrysin complex showed strong stability in docking and molecular dynamics analyses.

Beyond disease-target prediction, chrysin has been reported as a major phytochemical constituent in Salvia heldreichiana, where HPLC analysis identified it alongside rosmarinic acid, p-coumaric acid, and 4-hydroxybenzoic acid. In that work, chrysin also showed strong binding affinity in molecular docking against selected protein targets. Similarly, in a study of flavonoid derivatives from red propolis, chrysin demonstrated favorable docking and molecular dynamics behavior against Staphylococcus aureus sortase A, and it showed significant antibiofilm activity in vitro.